Thioanthranilsaeure | 32187-15-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Thioanthranilsaeure
• 英文别名: 2-aminobenzenecarbothioic S-acid
• CAS: 32187-15-8
• 化学式: C₇H₇NOS
• 分子量: 153.205
• InChiKey: WFHFVCFAKGYGPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  Thioanthranilsaeure 、 2-溴-1-间甲苯-乙酮 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以65%的产率得到S-[2-(3-methylphenyl)-2-oxoethyl]-2-aminobenzenecarbothioate
  参考文献：
  名称：

  来自 Quinolin-4(1H)-one 骨架的一些对称二硫化物的有效合成和细胞毒活性

  摘要：

  描述了含有 2-(取代苯基)quinolin-4(1H)-one 环的新型有机二硫化物的制备。该合成从用各种溴苯乙酮酯化的硫代邻氨基苯甲酸开始。在三氟乙酸中环化所得苯甲酰硫代邻氨基苯甲酸酯，得到 2-(取代苯基)-3-硫烷基喹啉-4(1H)-酮和 3,3'-二硫烷二基双 [2-(取代苯基)喹啉-4(1H) 的混合物-那些]。在邻二甲苯中加热混合物，得到高纯度的 3,3'-二硫烷二基双[2-(取代苯基)喹啉-4(1H)-酮]。二硫化物对包括多抗性亚克隆在内的各种癌细胞系表现出显着的体外细胞毒性。报告和讨论了获得的数据。（© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009）

  DOI：

  10.1002/ejoc.200900428

文献信息

• PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS
  申请人：Dellinger Douglas J.

  公开号：US20100076183A1

  公开（公告）日：2010-03-25

  A nucleoside monomer that is protected by a thionocarbamate protecting group is provided, as well as a method for making a polynucleotide that uses the same. Also provided is a polynucleotide synthesis method that employs a diamine to deprotect a protected polynucleotide.

  提供了一种由硫代氨基甲酸酯保护基保护的核苷单体，以及使用该核苷单体制备多核苷酸的方法。还提供了一种利用二胺去保护受保护多核苷酸的多核苷酸合成方法。
• Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain
  申请人：RUDOLPHI Karl

  公开号：US20110021505A1

  公开（公告）日：2011-01-27

  The present invention relates to the use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides of the formula I, wherein A and R 1 to R 6 have the meanings indicated in the claims, for treating pain and for manufacturing a medicament for the treatment of pain.

  本发明涉及使用式I中的磺酰基取代的2-磺酰氨基苯甲酸N-苯基酰胺，其中A和R1至R6具有声明中所示的含义，用于治疗疼痛并制造用于治疗疼痛的药物。
• ANTITUMORAL TERPENOID PHARMACEUTICAL COMPOSITION 'ABISILIN' EXHIBITING ANGIOGENESIS-INHIBITING ACTION
  申请人：Obschestvo S Ogranichennoy Otvetstvennostyu "Initium-Pharm"

  公开号：EP2275112A1

  公开（公告）日：2011-01-19

  The invention relates to medicine and chemical and pharmaceutical industry, and concerns to a pharmaceutical for treating diseases associated with angiogenesis disorders, in particular, to a method for treating oncological diseases of various geneses, by means of inducing angiogenesis inhibition adjuvant to the direct antitumor, anti-recurrent, and antimetastatic effect, as well as the associated activation of endogenous apoptosis. The invention is accomplished by use of a new oral dosage form Abisilin containing, as ingredients, natural terpene compounds (isoprenoids) derived from coniferous trees of the Pinaceae family, this dosage form comprising: sesquiterpenoids (3 to 6%); neutral terpenoids (11 to 15%); diterpene acids (23 to 28%); triterpene acids (8 to 16%); unsaturated and saturated fatty acids (0.1 to 0.3%); phenolic compounds (0.1 to 0.2%); monoterpenoids being the rest, wherein the bornyl acetate content is at least 10.0% relative to the total terpenes composition. The use of the new oral dosage form Abisilin, the substances whereof are known to exhibit immunomodulatory, antibacterial, anti-inflammatory, pain-releasing, wound-healing, and other pharmacologically significant effects; which lacks counter-indications or toxic effects; and which is suitable for use together with various agents in a complex therapy, is intended to provide a new therapeutic approach and to enhance the efficiency of treating oncologic and many other diseases associated with angiogenesis disorders.

  本发明涉及医学和化学制药工业，涉及一种用于治疗与血管生成障碍有关的疾病的药物，特别是涉及一种通过诱导血管生成抑制辅助直接抗肿瘤、抗复发和抗转移作用以及相关的内源性细胞凋亡激活来治疗各种基因肿瘤疾病的方法。本发明是通过使用一种新的口服剂型 Abisilin 来实现的，该剂型含有从松科针叶树中提取的天然萜类化合物（异戊烯类）作为成分，该剂型包括：倍半萜类（3 至 6%）；中性萜类（11 至 15%）；二萜酸（23 至 28%）；三萜酸（8 至 16%）；不饱和及饱和脂肪酸（0.1%至 0.3%）；酚类化合物（0.1%至 0.2%）；其余为单萜类化合物，其中乙酸冰片酯的含量相对于萜类化合物总成分至少为 10.0%。新口服剂型 Abisilin 的使用旨在提供一种新的治疗方法，并提高治疗肿瘤和许多其他与血管生成障碍有关的疾病的效率。
• Protected monomer and method of final deprotection for RNA synthesis
  申请人：Agilent Technologies, Inc.

  公开号：US10597421B2

  公开（公告）日：2020-03-24

  A method of deprotecting a solid support bound polynucleotide comprising at least one 2′-protected ribonucleotide in which a step of contacting the polynucleotide with a composition comprising a diamine is performed under conditions sufficient to deprotect and cleave the polynucleotide which remains retained on the solid support.

  一种对包含至少一种 2′-保护的核糖核苷酸的固体支持物结合的多核苷酸进行脱保护的方法，其中将多核苷酸与包含二胺的组合物接触的步骤是在足以对保留在固体支持物上的多核苷酸进行脱保护和裂解的条件下进行的。
• Non-toxic corrosion-protection pigments based on manganese
  申请人：——

  公开号：US20040011252A1

  公开（公告）日：2004-01-22

  Corrosion-inhibiting pigments based on manganese are described that contain a trivalent or tetravalent manganese/valence stabilizer complex. An inorganic or organic material is used to stabilize the trivalent or tetravalent manganese ion to form a compound that is sparingly soluble, exhibits low solubility, or is insoluble in water, depending upon the intended usage. Specific stabilizers are chosen to control the release rate of trivalent or tetravalent manganese during exposure to water and to tailor the compatibility of the powder when used as a pigment in a chosen binder system. Stabilizers may also modify the processing and handling characteristics of the formed powders. Manganese/valence stabilizer combinations are chosen based on the well-founded principles of manganese coordination chemistry. Many manganese-valence stabilizer combinations are presented that can equal the performance of conventional hexavalent chromium or tetravalent lead systems. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

  以锰为基础的缓蚀颜料含有三价或四价锰/价稳定剂复合物。一种无机或有机材料可用于稳定三价或四价锰离子，从而形成一种可少量溶解、溶解度低或不溶于水的化合物，具体取决于预期用途。选择特定的稳定剂是为了控制三价锰或四价锰在遇水时的释放率，并调整粉末在所选粘合剂体系中用作颜料时的相容性。稳定剂还可以改变成型粉末的加工和处理特性。锰/价稳定剂组合的选择是基于锰配位化学的基本原理。文中介绍了许多锰价稳定剂组合，其性能与传统的六价铬或四价铅体系相当。需要强调的是，提供本摘要是为了符合要求提供摘要的规则，以便检索者或其他读者快速确定技术公开的主题。提交本摘要的前提是，本摘要不用于解释或限制权利要求的范围或含义。